Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 19/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 17/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 14/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.48 |
| ▸ | MTOR | P42345 | 7/20 | 0.48 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
| ▸ | CHUK | O15111 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1368414 | 0.88 | LMNA (0.46) | PIK3CGPIK3CDPIK3CB | |
| SCHEMBL17203294 | 0.86 | PIK3CD (0.50) | PIK3CGPIK3CDPIK3CBPIK3CAMTOR | |
| SCHEMBL17203950 | 0.86 | PIK3CG (0.51) | PIK3CGPIK3CDPIK3CBPIK3CAMTOR | |
| SCHEMBL17204003 | 0.84 | KMT2A (0.51) | PIK3CGPIK3CDPIK3CBPIK3CAMTOR | |
| SCHEMBL19832788 | 0.84 | LMNA (0.43) | — | |
| SCHEMBL3417603 | 0.80 | CA1 (0.52) | IKBKBCHUK | |
| SCHEMBL18429750 | 0.79 | PIK3CD (0.50) | PIK3CGPIK3CDPIK3CBMTOR | |
| SCHEMBL17203702 | 0.79 | NPC1 (0.48) | PIK3CGPIK3CDPIK3CBPIK3CAIKBKB | |
| SCHEMBL13585634 | 0.79 | ALDH1A1 (0.56) | PIK3CGPIK3CDPIK3CBPIK3C3IKBKB | |
| SCHEMBL17203592 | 0.78 | ALDH1A1 (0.59) | IKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106458979-B | Aminopyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | 诺华股份有限公司 | 2020-03-27 | — | — | CN | disclosed |
| EP-3134396-B1 | AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2019-09-18 | — | — | EP | disclosed |
| EP-3134396-B1 | AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2019-09-18 | — | — | EP | disclosed |
| US-10112926-B2 | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors | NOVARTIS AG (CH) | 2018-10-30 | — | — | US | disclosed |
| US-20180243297-A1 | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | NOVARTIS AG (CH) | 2018-08-30 | — | — | US | disclosed |
| US-10004732-B2 | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | NOVARTIS AG (CH) | 2018-06-26 | — | — | US | disclosed |
| US-10004732-B2 | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | NOVARTIS AG (CH) | 2018-06-26 | — | — | US | disclosed |
| US-10004732-B2 | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | NOVARTIS AG (CH) | 2018-06-26 | — | — | US | disclosed |
| EP-3134395-B1 | PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2018-01-31 | — | — | EP | disclosed |
| US-9862711-B2 | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | NOVARTIS AG (CH) | 2018-01-09 | — | — | US | disclosed |
| US-20170042889-A1 | AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-02-16 | — | — | US | disclosed |
| US-20170037032-A1 | AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-02-09 | — | — | US | disclosed |
| US-20170037032-A1 | AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-02-09 | — | — | US | disclosed |
| US-20170037032-A1 | AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-02-09 | — | — | US | disclosed |
| US-20170029414-A1 | PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-02-02 | — | — | US | disclosed |
| US-20170029414-A1 | PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-02-02 | — | — | US | disclosed |
| US-20170029414-A1 | PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-02-02 | — | — | US | disclosed |
| WO-2015162459-A1 | AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-10-29 | — | — | WO | disclosed |
| WO-2015162461-A1 | PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-10-29 | — | — | WO | disclosed |
| WO-2015162456-A1 | AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029414-A1 | PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PI4KA, PI4K2B, PIP5K1B | PIK3CG 17/4885PIK3CD 13/4885PIK3CB 12/4885 |
| US-20170037032-A1 | AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PI4KA, PIP4K2B, PHKG1 | PIK3CG 16/4885PIK3CD 15/4885PIK3CB 13/4885 |
| US-20180243297-A1 | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | PI4KA, PIP5K1B, PIP4K2B | PIK3CG 18/4885PIK3CD 15/4885PIK3CB 13/4885 |
| US-10112926-B2 | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors | PI4KA, PIP4K2B, PHKG1 | PIK3CG 16/4885PIK3CD 15/4885PIK3CB 13/4885 |
| US-10004732-B2 | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | PI4KA, PIP5K1B, PIP4K2B | PIK3CG 18/4885PIK3CD 15/4885PIK3CB 13/4885 |
| US-20170042889-A1 | AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PI4KA, PIP5K1B, PIP4K2B | PIK3CG 18/4885PIK3CD 15/4885PIK3CB 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.